A 1 -A 2 9 8 of ICC, in a setting of 70% vaccination coverage. The incremental ratio of costeffectiveness (IRCE) was R$ 1,200 for each year of quality-adjusted life (QALY) saved. The sensitivity analysis confirms the robustness of this result, and duration of immunity was the parameter with greater variation in. CONCLUSIONS: Vaccination has a favorable profile in terms of cost-utility, and its inclusion in the immunization schedule would result in substantial reduction in incidence and mortality of ICC in amazonic region of Brazil.
OBJECTIVES:
To determine the dose relativity of sevelamer hydrochloride (SH) and lanthanum carbonate (LC) monotherapy under real-world clinical conditions in the USA. METHODS: A post hoc analysis of an open-label, post-marketing study of patients (n = 2763) with end-stage renal disease (ESRD) in a real-world clinical setting in the USA. The analysis evaluated patients who converted from SH monotherapy at baseline to LC monotherapy for 16 weeks (12 week titration phase, 4 week maintenance period). Serum phosphate (P) levels and daily P binder dose were assessed at baseline and at weeks 12 and 16. RESULTS: A total of 953 patients were taking SH monotherapy at baseline; their mean SH dose was 7644±3660 mg/day and mean serum P level was 5.88±1.69 mg/dL. After 16 weeks of LC monotherapy, mean LC dose was 2800±938 mg/day (SH:LC doserelativity 2.8) and mean P level was 5.93±1.85 mg/dL. In the subgroup of patients (n=191; 20%) receiving SH >7200 to ≤9600 mg/day (mean dose 9294±601 mg/day) at baseline, mean P level was 6.10±1.68 mg/dL. After LC treatment, their mean LC dose was 3018±800 mg/day (dose-relativity 3.1), and mean P level was 6.42±1.88 mg/dL. Patients (n=192; 20%) receiving SH >9600 mg/day (mean dose 13171±2388 mg/day) at baseline had a mean P level of 6.22±1.78 mg/dL. After LC treatment, their mean LC dose was 3156±808 mg/day (dose-relativity 4.2) and mean P level was 6.25±1.87 mg/dL. CONCLUSIONS: SH:LC dose relativity in the overall patient population was 2.8, in agreement with previous studies. However, the present study demonstrates that patients who require higher SH doses to maintain P control (>7200 mg/day; ~40% of patients) had higher SH:LC dose relativities (3.1-4.2). These findings have implications for the cost-effectiveness of P binder therapy in the treatment of patients with ESRD and hyperphosphatemia.
PHS43 PRODUCTIVITY LOSS COSTS ATTRIBUTABLE TO OVERWEIGHT OR OBESITY IN WORKING ASTHMA PATIENTS IN THE UNITED STATES
Choi IS 1 , Chang CW 1 , Kim CM 2 , Suh DC 1 1 Chung-Ang University, Seoul, South Korea, 2 Catholic University College of Medicine, Seoul, South Korea OBJECTIVES: To estimate annual productivity loss costs attributable to being overweight or obese in working adults with asthma patients in the US. METHODS: Working asthma patients (18-64 years old) were identified using the 2003-2009 Medical Expenditure Panel Survey (MEPS). Asthma patients were identified by self-reported diagnosis, Clinical Classification Codes of 128, or ICD-9-CM code of 493 and the identified patients were classified as normal-weight (18.5≤BMI<25), overweight (25≤BMI<30), and obese (BMI≥30). Productivity loss costs, which were measured based on missed work days due to illness or injury for one year and the hourly wage, were estimated using a two-part model to adjust for patients with zero costs. To estimate the productivity loss costs attributable to being overweight or obese, costs were estimated by assuming every patient is overweight or obese (i.e., treating the indicator variable as equal to 1) and re-estimating by assuming every patient is normal (i.e., treating the indicator variable as equal to 0). Then, the mean differences between the two estimated costs were considered the productivity loss costs attributable to overweight or obesity in asthma patients. All costs were converted to 2011 US dollars using the Consumer Price Index. RESULTS: Annual average productivity loss costs attributable to obesity were $697(95%CI:$614-$780) per patient, 45% higher than overweight (at $480, 95%CI:$397-$563) and 92% higher than normal (at $363, 95%CI:$298-$428). The productivity loss costs in working asthma patients increased as patients were obese, older, or female. Also, the productivity loss costs attributable to overweight or obesity in working asthma patients were estimated at $89 (95%CI:$87-$91) or $250 (95%CI:$246-$254) per person per year, respectively. CONCLUSIONS: The productivity lost costs attributable to overweight and obesity in working US adults with asthma were substantial. To reduce the economic burden of treating asthma patients and enhance productivity, this study further highlights the importance of weight control. 
PHS44

DRIVERS OF RESOURCE UTILIZATION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
OBJECTIVES:
Polycystic kidney disease (PKD) is a genetic disorder affecting nearly 1 in 1000 Americans. Autosomal dominant PKD (ADPKD) occurs in both children and adults with symptoms often occurring in middle age. The objective of this retrospective study was to assess hospital-based utilization among patients with ADPKD. METHODS: A retrospective study of 1409 patients hospitalized in 2009 with a diagnosis of ADPKD in 71 hospitals continuously submitting over 36 months from the MedAssets health system database was conducted. Subsequent hospital visits were identified over a 24 month follow-up period. Age and gender as well as clinical complications, comorbidities and measures of utilization including number of visits and length of stay (LOS) were described. Multivariate regression was used to identify significant drivers of hospital-based utilization. RESULTS: The sample population had a mean age of 50.6 years and was 51% male. Patients had an average of 17 outpatient and 2.5 inpatient visits. Average LOS was 20.6 days, 45% were diagnosed with end stage renal disease (ESRD) and 24% received hemodialysis. Over 15.0% required a kidney transplant while 3.3% died in the hospital. Comorbidities included diabetes 21.9%, congestive heart failure (CHF) 12.6%, cardiopulmonary disease (CPD) 14.7%, cardiovascular disease (CVD) 11.3% and malignancy/tumor 12.3%. ESRD (1.3 visits, P<0.001), kidney transplant (2.0 visits, p<.0001), (1.4 visits, p<.0001), CPD (1.3 visits, p<.0001), CVD (1.4 visits, p<.0001), malignancy (1.3 visits, p<0.05) and previous myocardial infarction (1.3 visits, p<0.05) were associated with more visits. Similarly, ESRD (1.8 days, <.0001) and kidney transplant (1.5 days, p=0.0005) were significantly associated with higher inpatient LOS. CONCLUSIONS: Patients with ADPKD consume a significant amount of health care resources, especially patients reaching the end stage of the disease. Further research is required to understand the effect of interventions/treatments on mitigating the progress of this disease.
PHS45
SHORT-TERM RELATIONSHIPS BETWEEN ELECTRONIC HEALTH RECORD SYSTEM INTEGRITY IN EMERGENCY DEPARTMENTS AND HEALTH CARE RESOURCE UTILIZATION AMONG PATIENTS WITH MENTAL DISORDERS
Tang DH, Warholak TL The University of Arizona, Tucson, AZ, USA OBJECTIVES: To assess patient emergency department (ED) waiting time, hospitalization rate immediately following ED visit, number of medications prescribed, and length of stay in ED among practices with various levels of electronic health record (EHR) functionality pertaining to mental illnessrelated ED visits. METHODS: Data from 2006-2009 Centers for Disease Control and Prevention National Hospital Ambulatory Medical Care Survey ED files were used for this retrospective, cross-sectional study. Mental disorders were identified via: 1) International Classification of Diseases, Ninth Revision, Clinical Modification codes based on definitions by American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, and 2) mental health-related reason for visits as determined by the National Center for Health Statistics. EHR use among organizations was classified as no EHR, some EHR, basic EHR, and fully functional EHR based on the number and level of available features. Negative binomial regression models were applied using waiting time and visit length as outcome variables, while logistic and ordered logistic regression models were applied using hospitalization rate and number of medications prescribed as dependent variables, respectively. Regression analyses adjusted for patient demographics (age, gender, race/ethnicity, region/location, education, income, insurance status), level of triage and comorbidity, and hospital ownership status. To provide national estimates, all results were weighted and used standard errors calculated via Taylor-series approaches. RESULTS: Of the 24.3 million ED visits identified, 37.2%, 33.4%, and 6.0% included some, basic, and fully functional EHRs, respectively. Having any sort of EHR was associated with 24% greater odds of hospitalization (p=0.032).
